Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12%

Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine, intismeran autogene, met key goals in a Phase 3 trial for advanced melanoma. The combination with Merck’s Keytruda showed statistically significant improvements in recurrence-free survival and reduced cancer spread compared to Keytruda alone. Moderna stock surged 177% to $174.38, while Merck climbed 12% to $152.22. This marks the first Phase 3 success for any mRNA-based cancer therapy.

What the trial proved

The Phase 3 INTerpath-001 trial tested intismeran plus Keytruda in 1,137 patients with high-risk melanoma whose tumors had been surgically removed. The combination met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival. The companies reported statistically significant improvements over Keytruda alone, though exact survival numbers were not disclosed. The trial will continue to measure overall survival benefit.

Why this matters for investors

Meyka grades Moderna a B with a 12-month forecast of $58.61, suggesting the stock is significantly overbought after today’s 177% surge. The RSI stands at 92.04, indicating extreme overbought conditions. Merck carries a B+ grade with a $148.17 forecast, implying modest downside from $152.22. Analyst consensus favors both stocks, but Moderna’s valuation now reflects years of future success priced in immediately.

Historical significance and next steps

This is the first Phase 3 win for a personalized neoantigen vaccine and the first mRNA cancer therapy to succeed in late-stage trials. Merck’s research chief said the companies will discuss regulatory strategy with agencies in the next few months. Data will be presented at an upcoming international medical meeting before any U.S. approval filing. Melanoma accounts for only 1% of skin cancers but causes most skin cancer deaths.

Wealth created and stock momentum

Moderna founder Robert Langer’s stake, estimated at 3%, jumped from $730 million to $1.7 billion. CEO Stephane Bancel’s net worth rose $2.5 billion to $4.8 billion. Founder Noubar Afeyan gained $184 million. Moderna’s volume hit 188 million shares, nearly 27 times its daily average. The stock closed at $174.38 after opening at $116.02, a gain of $111.42 in one day.

Final Thoughts

Moderna’s 177% spike reflects genuine clinical progress but leaves little room for disappointment. Meyka data and technicals signal extreme overbought conditions; investors should wait for a pullback or regulatory clarity before buying.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.